Table 3 Predicted effect of screening strategies on cancer rates and cost-effectiveness
Screening strategy and test | Average lifetime reduction cancer incidence | Average lifetime reduction cancer mortality | Average reduction cumulative incidence 0-64 years | Cost-effectiveness ratio compared to no intervention (US$ / LYS) †|
|---|---|---|---|---|
Once-lifetime (35 years) | Â | Â | Â | Â |
VIA only | 7% | 8% | 8% | 557 |
VIA/VILI | 8% | 10% | 10% | 629 |
careHPV@1.0 pg/ml | 10% | 12% | 12% | 959 |
careHPV@0.5 pg/ml | 10% | 12% | 13% | 909 |
Twice-lifetime (35+45 years) | Â | Â | Â | Â |
VIA only | 13% | 16% | 17% | 611 |
VIA/VILI | 16% | 18% | 20% | 689 |
careHPV@1.0 pg/ml | 19% | 22% | 24% | 1,032 |
careHPV@0.5 pg/ml | 21% | 24% | 25% | 985 |
10 yearly (30-59 years) | Â | Â | Â | Â |
VIA only | 17% | 19% | 20% | 665 |
VIA/VILI | 19% | 22% | 23% | 744 |
careHPV@1.0 pg/ml | 24% | 28% | 29% | 1,074 |
careHPV@0.5 pg/ml | 24% | 28% | 29% | 1,071 |
5 yearly (30-59 years) | Â | Â | Â | Â |
VIA only | 27% | 32% | 33% | 796 |
VIA/VILI | 31% | 36% | 37% | 916 |
careHPV@1.0 pg/ml | 37% | 43% | 44% | 1,395 |
careHPV@0.5 pg/ml | 37% | 43% | 44% | 1,391 |
IARC recommended | Â | Â | Â | Â |
VIA only | 37% | 43% | 41% | 1,213 |
VIA/VILI | 41% | 47% | 45% | 1,427 |
careHPV@1.0 pg/ml | 47% | 54% | 52% | 2,269 |
careHPV@0.5 pg/ml | 48% | 54% | 52% | 2,263 |